Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Completed No phase listed Observational

Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

NCT00899509
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
3
States / cities
Sioux City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

NCT02066532
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
Interventions
Ruxolitinib, Trastuzumab
Drug
Lead sponsor
Dawn L. Hershman
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional Results available

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

NCT01091428
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
Interventions
Alisertib, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
The Bronx, New York • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial for Large ER-Negative Breast Cancers

NCT01869192
View directory record Official record
Conditions
Malignant Neoplasm of Female Breast
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Capecitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 30, 2026, 8:48 PM EDT
Active, not recruiting No phase listed Observational

Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer

NCT04897009
View directory record Official record
Conditions
Invasive Breast Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional Results available

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

NCT00721409
View directory record Official record
Conditions
Breast Cancer
Interventions
PD 0332991, letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
51
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 30, 2026, 8:48 PM EDT
Recruiting Not applicable Interventional

Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors

NCT07587957
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise + transcranial alternating current stimulation (Ex+tACS), Control
Behavioral
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 1 Interventional

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

NCT00316875
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, Doxil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Not applicable Interventional Results available

Effects of Myofascial Massage and Patient-therapist Communication Levels on Shoulder Muscle Properties in Breast Cancer Survivors With Myofascial Pain

NCT06679400
View directory record Official record
Conditions
Pain, Myofacial
Interventions
Massage
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Recruiting Not applicable Interventional

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

NCT07698314
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Conditioning Resistance Training, Strength Resistance Training, Hypertrophy Resistance Training
Behavioral
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
20 Years to 89 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

NCT00777101
View directory record Official record
Conditions
Advanced Breast Cancer, Breast Cancer
Interventions
Neratinib, Lapatinib, Capecitabine
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
44
States / cities
Tucson, Arizona • Murrieta, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 30, 2026, 8:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881
View directory record Official record
Conditions
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Adela, Inc
Industry
Eligibility
40 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Completed No phase listed Observational

A Comparison of Primary Care and Traditional Internal Medicine Residents

NCT00224224
View directory record Official record
Conditions
Breast Cancer Screening, Cervical Cancer Screening, Cholesterol Screening, Asthma Admission Rate, Diabetes Management
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional Results available

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

NCT01441596
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Vinorelbine, Investigator's choice of treatment, afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646
View directory record Official record
Conditions
Breast Cancer
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 30, 2026, 8:48 PM EDT
Withdrawn Phase 2 Interventional

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

NCT00615524
View directory record Official record
Conditions
Hormone-receptor Positive Breast Cancer
Interventions
exemestane and pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 30, 2026, 8:48 PM EDT
Completed No phase listed Observational

Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes

NCT06078761
View directory record Official record
Conditions
Breast Cancer
Interventions
Healthy Eating Active Lifestyle (HEAL) Program
Behavioral
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Phase 1 Interventional

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

NCT01339442
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
BKM120, Fulvestrant, biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Early Phase 1 Interventional

Intraoperative Imaging of Breast Cancer With Indocyanine Green

NCT01796041
View directory record Official record
Conditions
Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
Interventions
Indocyanine Green
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 30, 2026, 8:48 PM EDT
Withdrawn Phase 1Phase 2 Interventional

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

NCT04315246
View directory record Official record
Conditions
Leptomeningeal Metastasis, Solid Tumor, Adult
Interventions
radiolabeled DPTA-omburtamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 30, 2026, 8:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

NCT00620373
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
969 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 30, 2026, 8:48 PM EDT
Active, not recruiting Not applicable Interventional

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

NCT05223322
View directory record Official record
Conditions
Breast Cancer
Interventions
Taking Charge during Treatment (TCT) Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 8:48 PM EDT
Terminated Phase 1 Interventional

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

NCT05553522
View directory record Official record
Conditions
Brain Metastases, HER2-positive Breast Cancer
Interventions
Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Combination Product
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 30, 2026, 8:48 PM EDT